SunHydrogen pays $3 million for NewHydrogen shares and warrants, reporting a 42.7% stake and possible board seat
SEC filings show SunHydrogen bought 203,650,000 NewHydrogen shares and warrants for 407,300,000 more in a private placement, and may seek a seat on its board.
Drafted by the Loro Desk from public records and published automatically after a 24-hour hold. Published without editorial review.
SunHydrogen paid $2,999,764.50 for 203,650,000 NewHydrogen shares plus warrants for 407,300,000 more, reports beneficial ownership of 42.7% and may seek to put its chief executive or another designee on NewHydrogen's board, a Schedule 13D filed on 28 October 2026 shows.
- Price paid
- $2,999,764.50
- Shares bought
- 203,650,000
- Warrants
- 407,300,000 at $0.016203
- Reported stake
- 42.7% including warrant shares
- Filing
- Schedule 13D, 28 Oct 2026
SunHydrogen, Inc. (CIK 1481028) has paid $2,999,764.50 for 203,650,000 shares of NewHydrogen, Inc. (CIK 1371128) and warrants to buy up to 407,300,000 more, according to a Schedule 13D filed with the SEC on 28 October 2026. The filing gives 23 October 2026 as the date of the event.
The shares and warrants were bought in a private placement at $0.01473 per share. The warrants can be exercised immediately, for five years, at $0.016203 per share. SunHydrogen says it paid from its working capital (Schedule 13D, Item 3).
SunHydrogen reports beneficial ownership of 610,950,000 shares, counting the warrant shares, or 42.7% of the class. The filing bases that on 1,024,362,103 NewHydrogen shares outstanding as of 26 October 2026, and reports sole voting and dispositive power over all of them (Schedule 13D, Item 5).
The stated purpose is a strategic investment in NewHydrogen and exploring technical and commercial collaboration in renewable hydrogen production (Schedule 13D, Item 4).
SunHydrogen says it may acquire more shares by exercising the warrants, and may seek to have its chief executive or another designee elected to NewHydrogen's board. It says it has no plans for a merger, asset sales, delisting or other listed actions (Schedule 13D, Item 4).
The filing states there are no other contracts or understandings with anyone over NewHydrogen's securities, and does not file the purchase agreement as an exhibit (Schedule 13D, Items 6 and 7).
The filings do not state the terms of any collaboration between the two companies. Loro has made no approach to the company. Figures are as reported in NewHydrogen's SEC filings.
Primary sources
1 recordEvery factual claim above is drawn from these records. Each link resolves to the publisher’s own copy.